In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database
Aim: Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis. Materials & methods: This retrospective analysis used nationally representative hospital discharge data (2017–2020) to report discharge status, resource use and costs for hospitalizatio...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2022-12-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1797785010059608064 |
|---|---|
| author | Tiffany P Quock Anita D’Souza Michael S Broder Katalin Bognar Eunice Chang Marian H Tarbox |
| author_facet | Tiffany P Quock Anita D’Souza Michael S Broder Katalin Bognar Eunice Chang Marian H Tarbox |
| author_sort | Tiffany P Quock |
| collection | DOAJ |
| description | Aim: Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL)
amyloidosis. Materials & methods: This retrospective analysis used nationally representative hospital
discharge data (2017–2020) to report discharge status, resource use and costs for hospitalizations among
patients with AL amyloidosis. Results: Of 1341 patients identified, 92% were discharged alive and 8%
experienced in-hospital death. Compared with the average US hospital stay during 2017–2019 (4.7 days,
mean costs of $13,046 and mean charges of $54,496), hospital stays for AL amyloidosis were longer and
costlier (9.7 days, $27,098.61, $111,233.91), especially in patients with in-hospital death (12.2 days, $44,966,
$182,338.18). Conclusion: AL amyloidosis is associated with significant clinical and economic burden. |
| first_indexed | 2024-03-13T00:48:03Z |
| format | Article |
| id | doaj.art-120d60c611cf46489b43db11e9e2ffd1 |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-13T00:48:03Z |
| publishDate | 2022-12-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-120d60c611cf46489b43db11e9e2ffd12023-07-08T12:17:08ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132022-12-0112210.2217/cer-2022-0185In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare DatabaseTiffany P Quock0https://orcid.org/0000-0002-4861-4285Anita D’Souza1https://orcid.org/0000-0002-1092-5643Michael S Broder2https://orcid.org/0000-0002-2049-5536Katalin Bognar3https://orcid.org/0000-0001-8357-8569Eunice Chang4https://orcid.org/0000-0003-0177-6153Marian H Tarbox5https://orcid.org/0000-0002-0818-5113Health Economics and Outcomes Research, Prothena Biosciences Inc, South San Francisco, CA 94080, USAMedical College of Wisconsin, Milwaukee, WI 53226, USAReal World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA 90212, USAReal World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA 90212, USAReal World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA 90212, USAReal World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA 90212, USAAim: Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis. Materials & methods: This retrospective analysis used nationally representative hospital discharge data (2017–2020) to report discharge status, resource use and costs for hospitalizations among patients with AL amyloidosis. Results: Of 1341 patients identified, 92% were discharged alive and 8% experienced in-hospital death. Compared with the average US hospital stay during 2017–2019 (4.7 days, mean costs of $13,046 and mean charges of $54,496), hospital stays for AL amyloidosis were longer and costlier (9.7 days, $27,098.61, $111,233.91), especially in patients with in-hospital death (12.2 days, $44,966, $182,338.18). Conclusion: AL amyloidosis is associated with significant clinical and economic burden.al amyloidosishospitalizationmortality |
| spellingShingle | Tiffany P Quock Anita D’Souza Michael S Broder Katalin Bognar Eunice Chang Marian H Tarbox In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database Journal of Comparative Effectiveness Research al amyloidosis hospitalization mortality |
| title | In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database |
| title_full | In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database |
| title_fullStr | In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database |
| title_full_unstemmed | In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database |
| title_short | In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database |
| title_sort | in hospital mortality in amyloid light chain amyloidosis analysis of the premier healthcare database |
| topic | al amyloidosis hospitalization mortality |
| work_keys_str_mv | AT tiffanypquock inhospitalmortalityinamyloidlightchainamyloidosisanalysisofthepremierhealthcaredatabase AT anitadsouza inhospitalmortalityinamyloidlightchainamyloidosisanalysisofthepremierhealthcaredatabase AT michaelsbroder inhospitalmortalityinamyloidlightchainamyloidosisanalysisofthepremierhealthcaredatabase AT katalinbognar inhospitalmortalityinamyloidlightchainamyloidosisanalysisofthepremierhealthcaredatabase AT eunicechang inhospitalmortalityinamyloidlightchainamyloidosisanalysisofthepremierhealthcaredatabase AT marianhtarbox inhospitalmortalityinamyloidlightchainamyloidosisanalysisofthepremierhealthcaredatabase |